| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 07/20/2006 | US20060160742 Neuropeptide-2 receptor (Y-2R) agonists and uses thereof |
| 07/20/2006 | US20060160741 Dimeric TF antagonists |
| 07/20/2006 | US20060160740 Use of GLP-1 or analogs in treatment of stroke |
| 07/20/2006 | US20060160739 GRF-containing lyophilized pharmaceutical compositions |
| 07/20/2006 | US20060160738 Stem cell factor-like proteins and uses thereof |
| 07/20/2006 | US20060160737 Methods of using IL-1 antagonists to treat polymyalgia rheumatica and giant cell arteritis |
| 07/20/2006 | US20060160736 Pharmaceutical compositions and methods for restoring beta-cell mass and function |
| 07/20/2006 | US20060160735 Beta-peptoids with antimicrobial activity |
| 07/20/2006 | US20060160734 In situ method for treatment and repair of meniscal injuries |
| 07/20/2006 | US20060160733 Compositions and methods for treating and preventing heart tissue degeneration and uses thereof |
| 07/20/2006 | US20060160732 Compositions and methods for inhibiting cell senescence and hyperproliferative disorders |
| 07/20/2006 | US20060160731 Peptide nucleic acids |
| 07/20/2006 | US20060160730 Administering pro-adrenomedullin N-terminal 20 peptide to induce neovascularization; use in treating coronary artery disease, peripheral vascular disease, and wounds; skin and organ (including heart) grafts |
| 07/20/2006 | US20060160729 Methods and compositions for manipulating the guided navigation of endothelial tubes during angiogenesis |
| 07/20/2006 | US20060160728 Diagnostic and therapeutic use of ensandin-0138 gene and protein for neurodegenerative diseases |
| 07/20/2006 | US20060160727 3-Ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection |
| 07/20/2006 | US20060160726 Cyclic agonists and antagonists of C5a receptors and G protein-coupled receptors |
| 07/20/2006 | US20060160725 Protein or hydrolyzate/phospholipid complex; used to improve lipid metabolism; functional food comprising the complex; anticholesterol agents |
| 07/20/2006 | US20060160724 Preserving a hemoglobin blood substitute with a transparent overwrap |
| 07/20/2006 | US20060160723 Glycoproteins having lipid mobilising properties and therapeutic applications thereof |
| 07/20/2006 | US20060160722 Administering glucagon daily as part of a diabetes treatment regimen |
| 07/20/2006 | US20060160721 Method of plasma lipidation to prevent, inhibit and/or reverse atherosclerosis |
| 07/20/2006 | US20060160720 Protein stabilization in solution |
| 07/20/2006 | US20060160214 Engineered intervertebral disc tissue |
| 07/20/2006 | US20060160187 Combinatorial interleukin-2 muteins |
| 07/20/2006 | US20060160177 Peptide extended glycosylated polypeptides |
| 07/20/2006 | US20060160176 High throughput cell-based functional assays and using cells, e.g., HEK-293 cells that express a G protein such as G alpha 15, G alpha 16 or gustducin. |
| 07/20/2006 | US20060160159 Identification of actinobacillus actinomycetemcomitans antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases |
| 07/20/2006 | US20060160158 Target and method for inhibition of bacterial rna polymerase |
| 07/20/2006 | US20060160154 Materials and methods for detection and treatment of breast cancer |
| 07/20/2006 | US20060160150 Solid phase synthesis; antibodies; kits |
| 07/20/2006 | US20060160147 Recombinant cell line |
| 07/20/2006 | US20060160145 Assay that makes use of the interaction of early pregnancy factor (EPF) or an EPF-related peptide with a human dorsal root receptor (hDRR) or hDRR related receptor; also useful to determine whether the test compound is an agonist or antagonist of hDRRs |
| 07/20/2006 | US20060160143 Mitogenic oxygenases |
| 07/20/2006 | US20060160142 Phosophoinositoglycan binding proteins |
| 07/20/2006 | US20060160132 Diagnositics and therapeutics for diseases associated with g-protein coupled receptor hm74a (hm74a) |
| 07/20/2006 | US20060160103 Mammalian neuralized family transcriptional regulators and uses |
| 07/20/2006 | US20060160088 Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 40 (gpr40) |
| 07/20/2006 | US20060160076 Methods of treating and diagnosing diabetes with cx3cr1 modulators |
| 07/20/2006 | US20060159782 Material for promoting skin basement formation |
| 07/20/2006 | US20060159769 Methods compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue |
| 07/20/2006 | US20060159767 Nanoparticulate bicalutamide formulations |
| 07/20/2006 | US20060159733 Method of providing hemostasis to a wound |
| 07/20/2006 | US20060159731 Multi-layer collagenic article useful for wounds healing and a method for its production thereof |
| 07/20/2006 | US20060159719 Method and composition for inhibiting cardiovascular cell proliferation |
| 07/20/2006 | US20060159705 Purification of HBV antigens for use in vaccines |
| 07/20/2006 | US20060159700 Multivalent immunogenic composition containing RSV subunit composition and influenza virus preparation |
| 07/20/2006 | US20060159692 Transcriptional factor inducing apoptosis in cancer cell |
| 07/20/2006 | US20060159687 Modified aerolysin and methods of use for treating lung cancer |
| 07/20/2006 | US20060159686 Natural killer cell activating factor II |
| 07/20/2006 | US20060159685 Of given sequence; immunomodulators; prophylaxis or treatments for cancers |
| 07/20/2006 | US20060159682 Monoclonal antibodies (MAbs) against tumor-associated antigens, the preparation and use thereof |
| 07/20/2006 | US20060159679 Stabilized lyophilized compositions comprising tissue factor pathway inhibitor or tissue factor pathway inhibitor variants |
| 07/20/2006 | US20060159678 Modulators of cytokine mediated signaling pathways and integrin alphabeta3 receptor antagonists for combination therapy |
| 07/20/2006 | US20060159677 Tumour necrosis factor peptide binding antibodies |
| 07/20/2006 | US20060159674 Drug screening; modulating amyloid beta -protein-mediated cell death using agents that interfere with the activity of FISH adaptor protein; neurodegenerative diseases |
| 07/20/2006 | US20060159671 Uses of sysnergistic bacteriophage lytic enzymes for prevention and treatment of bacterial infections |
| 07/20/2006 | US20060159665 Seed tear resistant scaffold |
| 07/20/2006 | US20060159663 Growth factor encapsulation system for enhancing bone formation |
| 07/20/2006 | US20060159662 Therapeutic anti-melanoma compounds |
| 07/20/2006 | US20060159658 Methods of treating disease with glycosylated interferon |
| 07/20/2006 | US20060159657 Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders |
| 07/20/2006 | US20060159656 Formulations for IL-11 |
| 07/20/2006 | US20060159655 Treating immunological disorders using agonists of interleukin-21 / interleukin-21 receptor |
| 07/20/2006 | US20060159654 Interacting the immature dendritic cells with an antigen ex vivo so that the surface antigen is presented; inducing maturation ex vivo; and contacting with a modulator comprising TRANCE; an increased viability relative to a control dendritic cell not contacted with TRANCE |
| 07/20/2006 | US20060159653 Stabilized preparation containing protein |
| 07/20/2006 | US20060159652 Gd2 ligands |
| 07/20/2006 | US20060159651 Gradient molecular weight viscoelastic solutions |
| 07/20/2006 | US20060159646 Hair regenerator |
| 07/20/2006 | US20060159626 Method for administering a cytokine to the central nervous system and the lymphatic system |
| 07/20/2006 | US20060159620 Human kininogen D3 domain polypeptide as an anti-angiogenic and anti-tumor agent |
| 07/20/2006 | DE20014819U1 Medical use of inhibitors of serine/threonine protein phosphatase, for treatment or prevention of e.g. arteriosclerosis, cystic fibrosis and diabetes mellitus |
| 07/20/2006 | CA2603630A1 Modified exendins and uses thereof |
| 07/20/2006 | CA2594894A1 Method for delivering interferon-.beta. |
| 07/20/2006 | CA2594798A1 Il-10 related peptides for wound healing |
| 07/20/2006 | CA2594517A1 Treatment of skin diseases |
| 07/20/2006 | CA2594013A1 Methods and compositions related to modulating the extracellular stem cell environment |
| 07/20/2006 | CA2593818A1 Antibiotic 107891, its factors a1 and a2, pharmaceutically acceptable salts and compositions, and use thereof |
| 07/20/2006 | CA2593697A1 Pan-her antagonists and methods of use |
| 07/20/2006 | CA2593603A1 Use of a trpc channel for the treatment of a cardiovascular disease |
| 07/20/2006 | CA2593541A1 Identification of phospholipase a2 as target in cancer treatment, with special emphasis on colorectal cancer and its mechanism of action |
| 07/20/2006 | CA2593201A1 Method of treating or preventing tissue deterioration, injury or damage due to a neuro-, muscular- or neuro-muscular-degenerative disease, or restore tissue adversely affected by said disease |
| 07/20/2006 | CA2593198A1 Modified beta thymosin peptides |
| 07/19/2006 | EP1681355A1 Sequence-specific DNA recombination in eukaryotic cells |
| 07/19/2006 | EP1681354A2 Recombinant viruses coding for a glutamate decarboxylase (gad) |
| 07/19/2006 | EP1681350A2 Porphorymonas gingivalis polypeptides and polynucleotides |
| 07/19/2006 | EP1681348A1 MU-1 member of the cytokine receptor family |
| 07/19/2006 | EP1681305A2 Monoclonal and chimeric antibodies specific for human tumor necrosis factor |
| 07/19/2006 | EP1681304A2 Recombinant fusion proteins of growth hormone and serum albumin |
| 07/19/2006 | EP1681303A1 HASylated polypeptides, especially HASylated erythropoietin |
| 07/19/2006 | EP1681302A1 Novel protein and production process and use thereof |
| 07/19/2006 | EP1681301A1 Leishmania antigens for use in the therapy and diagnosis of Leishmaniasis |
| 07/19/2006 | EP1681300A1 Hybrid tetanus toxoid proteins that migrate retrogradely and transynaptically into the CNS |
| 07/19/2006 | EP1681064A1 Induction of antigen-specific T cells by interferon |
| 07/19/2006 | EP1681063A1 Agent for improving mental disorders |
| 07/19/2006 | EP1681062A1 Antibacterial drug for propionibacterium acnes |
| 07/19/2006 | EP1681051A1 Multi-layer controlled-release tablet comprising an active layer and one or more barrier layers |
| 07/19/2006 | EP1680677A1 Modulators of ms4a gene products |
| 07/19/2006 | EP1680507A2 Bacterial expression of protease inhibitors and variants thereof |
| 07/19/2006 | EP1680500A2 High temperature and alkaline stable catalase |